AJOVista LLC Makes New $99,000 Investment in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

AJOVista LLC bought a new position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) in the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 2,778 shares of the company’s stock, valued at approximately $99,000.

Other institutional investors have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. boosted its stake in IDEAYA Biosciences by 96.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,474 shares of the company’s stock worth $40,000 after purchasing an additional 723 shares during the period. Exchange Traded Concepts LLC grew its holdings in shares of IDEAYA Biosciences by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 4,806 shares of the company’s stock valued at $171,000 after buying an additional 1,219 shares in the last quarter. Callan Capital LLC acquired a new position in IDEAYA Biosciences during the fourth quarter valued at $239,000. Amalgamated Bank lifted its stake in IDEAYA Biosciences by 6.4% in the 3rd quarter. Amalgamated Bank now owns 7,205 shares of the company’s stock worth $194,000 after acquiring an additional 433 shares in the last quarter. Finally, Aigen Investment Management LP acquired a new stake in IDEAYA Biosciences during the 3rd quarter worth about $241,000. 98.29% of the stock is owned by hedge funds and other institutional investors.

IDEAYA Biosciences Trading Up 1.7 %

NASDAQ IDYA traded up $0.69 during trading on Friday, hitting $42.18. 356,005 shares of the company traded hands, compared to its average volume of 634,283. IDEAYA Biosciences, Inc. has a 12 month low of $18.50 and a 12 month high of $47.74. The business has a fifty day simple moving average of $42.74 and a 200 day simple moving average of $37.98. The company has a market capitalization of $3.15 billion, a P/E ratio of -21.41 and a beta of 0.83.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings data on Tuesday, February 20th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.05). The company had revenue of $3.90 million during the quarter, compared to the consensus estimate of $8.84 million. IDEAYA Biosciences had a negative net margin of 483.05% and a negative return on equity of 23.00%. IDEAYA Biosciences’s revenue for the quarter was down 3.0% on a year-over-year basis. Equities research analysts predict that IDEAYA Biosciences, Inc. will post -2.26 EPS for the current fiscal year.

Analysts Set New Price Targets

IDYA has been the subject of a number of research analyst reports. BTIG Research began coverage on shares of IDEAYA Biosciences in a research report on Friday, March 8th. They issued a “buy” rating and a $55.00 price target for the company. The Goldman Sachs Group increased their target price on shares of IDEAYA Biosciences from $36.00 to $53.00 and gave the stock a “buy” rating in a research report on Thursday, January 25th. JPMorgan Chase & Co. boosted their price target on shares of IDEAYA Biosciences from $51.00 to $57.00 and gave the company an “overweight” rating in a report on Friday, February 23rd. Citigroup upped their price target on shares of IDEAYA Biosciences from $40.00 to $60.00 and gave the stock a “buy” rating in a research note on Thursday, March 21st. Finally, Royal Bank of Canada lifted their price objective on IDEAYA Biosciences from $43.00 to $53.00 and gave the company an “outperform” rating in a research report on Wednesday, February 21st. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, IDEAYA Biosciences currently has a consensus rating of “Buy” and a consensus target price of $46.60.

Insider Activity

In related news, insider Briseno Andres Ruiz sold 2,000 shares of the firm’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $46.02, for a total value of $92,040.00. Following the transaction, the insider now directly owns 24,531 shares in the company, valued at approximately $1,128,916.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Briseno Andres Ruiz sold 2,000 shares of the stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $46.02, for a total transaction of $92,040.00. Following the completion of the sale, the insider now owns 24,531 shares in the company, valued at approximately $1,128,916.62. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Yujiro S. Hata sold 23,557 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $45.54, for a total value of $1,072,785.78. Following the completion of the sale, the chief executive officer now directly owns 677,887 shares in the company, valued at approximately $30,870,973.98. The disclosure for this sale can be found here. Insiders own 3.50% of the company’s stock.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.